Global Actinium-227 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Actinium-227 market size was valued at US$ 25.67 million in 2025 and is forecast to a readjusted size of US$ 75.39 million by 2032 with a CAGR of 17.2% during review period.
In 2025, global Actinium-227 production was approximately 198 grams, with an average global market price of around $126,000 per gram. That year, total global production capacity for Actinium-227 reached approximately 300 grams. The industry's average gross profit margin stood at approximately 71%. Actinium-227 is a highly radioactive isotope of the actinide element actinium (atomic number 89, mass number 227). While ^227Ac occurs naturally in the uranium-235 (^235U) decay chain, its natural abundance is too low to meet commercial demand; consequently, it is primarily produced through artificial nuclear reactions. With a half-life of approximately 21.77 years, ^227Ac decays via alpha and beta-minus (β⁻) processes into multiple daughter nuclides—including potent alpha-particle emitters capable of significant radiation-induced cell killing—making it a key candidate for Targeted Alpha Therapy (TAT). Compared to traditional beta-emitting radionuclides, alpha particles possess high energy, a short range, and intense localized destructive power, allowing for the precise targeting of tumor cells while minimizing damage to surrounding healthy tissue. Currently, ^227Ac is primarily used in radiopharmaceutical development—particularly for antibody-drug conjugates, peptide-based drugs, and small-molecule targeted therapies—as well as in nuclear chemistry research, the development of radioactivity standards, and the study of actinide chemical behavior.
The upstream sector of the ^227Ac value chain encompasses the supply of radium-226 (^226Ra) resources, the recovery of by-products from uranium mining, the preparation of high-purity target materials, and the operation of nuclear production facilities. Given the scarcity of natural ^227Ac, ​​commercial supply relies on artificial production methods; a well-established approach involves using ^226Ra as a parent nuclide and subjecting it to neutron irradiation, proton bombardment, or other nuclear reactions to generate ^227Ac, ​​followed by complex radiochemical separation to isolate the final product. This upstream segment faces significant technical barriers and stringent requirements regarding nuclear material sourcing, access to reactors or accelerators, radioactive waste management capabilities, and regulatory licensing. Currently, only a limited number of institutions worldwide—primarily national laboratories, research institutes, and specialized nuclear technology companies equipped with high-flux research reactors, accelerators, and radioisotope production capabilities—are capable of stable ^227Ac production. Factors such as long production cycles, limited raw material availability, and constrained production capacity serve as major bottlenecks limiting industry expansion. The midstream of the Actinium-227 (²²⁷Ac) value chain primarily encompasses radiochemical separation, high-purity processing, quality testing, and the preparation of radiopharmaceutical precursors. Since ²²⁷Ac produced via nuclear reactions is typically accompanied by other radionuclides—such as radium, thorium, and francium—purification techniques like ion exchange, solvent extraction, and chromatography are required to yield products with the high radiochemical purity necessary for medical and scientific applications. Purified ²²⁷Ac is generally supplied in forms such as chloride solutions and subsequently radiolabeled with antibodies, peptides, or small-molecule ligands to create radiopharmaceutical candidates for targeted alpha therapy (TAT) research. This midstream segment entails significant technical barriers, as it requires not only capabilities in nuclear chemical separation but also adherence to standards for quality control, aseptic manufacturing, radiation safety management, and pharmaceutical evaluation during drug development. Currently, the development of ²²⁷Ac-based drugs is advancing rapidly, with numerous biopharmaceutical companies and research institutions worldwide conducting research into ²²⁷Ac-based anti-cancer therapies. Downstream applications of ²²⁷Ac are primarily concentrated in nuclear medicine therapy, radiopharmaceutical development, and fundamental nuclear science research. Among these, targeted alpha therapy (TAT) represents the application area with the greatest future commercial potential. ²²⁷Ac and its decay progeny continuously emit alpha particles; when linked to targeting molecules that bind precisely to tumor cells, they can effectively destroy cancer cells, making them a key focus of innovative therapeutic research for conditions such as prostate cancer, neuroendocrine tumors, and hematological malignancies. Additionally, ²²⁷Ac is utilized in studies of nuclide decay and actinide chemistry, as well as in the development of radioactivity metrology standards. Demand for ²²⁷Ac is projected to grow steadily in the future, driven by the rapid expansion of the global radiopharmaceutical market, the rising need for precision cancer therapies, and the maturation of alpha-nuclide therapy technologies. However, due to limited production capacity and supply chain constraints linked to nuclear facilities, it remains a high-value, small-scale strategic radioisotope.
The primary driver for the development of Actinium-227 (^227Ac) is the advancement of Targeted Alpha Therapy (TAT) technology. Unlike traditional beta-emitting therapeutic radionuclides, ^227Ac releases high-energy alpha particles during decay; these are characterized by a short range, high local energy deposition, and potent cell-killing capabilities, enabling the precise destruction of tumor cells while minimizing impact on surrounding healthy tissue. In recent years, the rise of precision cancer therapy and the maturation of radiopharmaceutical conjugation technologies have spurred interest in ^227Ac-based radiopharmaceuticals, which show significant potential in treating conditions such as prostate cancer, hematologic malignancies, and neuroendocrine tumors. As more alpha-emitting therapeutic agents advance to clinical trials and commercialization, the demand for ^227Ac as a key therapeutic radionuclide is expected to rise steadily.
The continuous growth in the global cancer patient population, combined with the limitations of traditional treatments for certain advanced cancers, has accelerated the development of precision radiotherapies. With its long half-life (approximately 21.77 years), high alpha-particle emission efficiency, and nuclear physical properties conducive to long-term drug development, ^227Ac is recognized as a crucial alpha-emitting therapeutic radionuclide, following in the footsteps of Radium-223 (^223Ra) and Actinium-225 (^225Ac). Advances in bioconjugation technologies, antibody-based drugs, small-molecule targeting ligands, and nuclear medicine imaging have continuously expanded the potential applications of ^227Ac in radiopharmaceutical development. Meanwhile, increased investment by pharmaceutical companies and research institutions in alpha-emitting drug pipelines has further driven the need for ^227Ac supply chain development and industrialization.
A key constraint on the industrial development of ^227Ac is the ability to ensure a stable supply. Due to the extremely low natural abundance of ^227Ac, ​​commercial supply relies primarily on production via nuclear reactions and complex radiochemical separation techniques. Recent advancements in research reactors, high-energy accelerators, radiochemical separation, and automated radionuclide processing have gradually improved ^227Ac production efficiency and product quality control. Furthermore, the growing global emphasis on the security of the medical radioisotope supply chain has encouraged government agencies, research institutions, and enterprises to step up the construction of radionuclide production facilities. In the future, suppliers possessing Radium-226 resources, high-flux nuclear reaction capabilities, and radiochemical purification technologies will hold a competitive advantage in the market.
Report Scope
This report is a detailed and comprehensive analysis for global Actinium-227 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Actinium-227 market size and forecasts, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Actinium-227 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Actinium-227 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Actinium-227 market shares of main players, shipments in revenue ($ Million), sales quantity (Gram), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Actinium-227
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Actinium-227 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ORNL(DOE IP), Rosatom, Fusion Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Actinium-227 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Activity Concentration＜50Ci/g
Activity Concentration≥50Ci/g
Market segment by Product Form
Actinium-227 Solution
Actinium-227 Solid Compound
Actinium-227 Standard Source
Market segment by Chemical Purity
Research Grade Actinium-227
High Radiochemical Purity Actinium-227
Market segment by Production Source
Radium-226-derived Actinium-227
Uranium Series Separation Actinium-227
Accelerator-produced Actinium-227
Reactor-produced Actinium-227
Market segment by Application
Nuclear Medicine
Scientific Research
Major players covered
ORNL(DOE IP)
Rosatom
Fusion Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Actinium-227 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Actinium-227, with price, sales quantity, revenue, and global market share of Actinium-227 from 2021 to 2026.
Chapter 3, the Actinium-227 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Actinium-227 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Actinium-227 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Actinium-227.
Chapter 14 and 15, to describe Actinium-227 sales channel, distributors, customers, research findings and conclusion.